Literature DB >> 12466123

Loss of the EP2 prostaglandin E2 receptor in immortalized human keratinocytes results in increased invasiveness and decreased paxillin expression.

Raymond L Konger1, Glynis A Scott, Yvonne Landt, Jack H Ladenson, Alice P Pentland.   

Abstract

Prostaglandin E(2) (PGE(2)) receptor subtype EP(2), which is coupled to cAMP metabolism, is known to mediate proliferation of primary human keratinocytes in vitro. The effect of gain or loss of EP(2) receptors in immortalized human keratinocytes (HaCat cells) was examined. HaCat keratinocytes were transfected with sense or anti-sense constructs of the EP(2) receptor. Loss or gain of EP(2) expression was documented by immunoblot and associated changes in agonist-stimulated cAMP production. Loss or gain of EP(2) receptor expression correlated with alterations in plating efficiencies but with modest affects on growth. When cell lines were studied in an organ culture model, anti-sense clones were highly invasive compared with vector controls and sense transfectants. A marked increase in prostaglandin production is commonly seen in malignant lesions. Because prostaglandin receptors are known to undergo ligand-induced receptor down-regulation, we sought to determine whether EP(2) receptor down-regulation results in increased invasiveness. In vector controls, invasiveness was reproduced by ligand-dependent EP(2) receptor down-regulation as assessed by immunohistochemistry. In addition, loss of EP(2) receptor expression was associated with decreased paxillin expression, a critical component of focal adhesion assembly. Thus, down-regulation of EP(2) receptors represents a potential mechanism for neoplastic progression to an invasive phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466123      PMCID: PMC1850902          DOI: 10.1016/S0002-9440(10)64485-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  63 in total

1.  Prostaglandin deficiency promotes sensitization of adenylyl cyclase.

Authors:  S Weber; H Lemoine; H K Wasner
Journal:  Biol Chem       Date:  2000 May-Jun       Impact factor: 3.915

2.  Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration.

Authors:  S Desai; H April; C Nwaneshiudu; B Ashby
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

3.  Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor.

Authors:  J M Connolly; X H Liu; D P Rose
Journal:  Nutr Cancer       Date:  1996       Impact factor: 2.900

4.  The expression of prostaglandin E receptors EP2 and EP4 and their different regulation by lipopolysaccharide in C3H/HeN peritoneal macrophages.

Authors:  R Ikegami; Y Sugimoto; E Segi; M Katsuyama; H Karahashi; F Amano; T Maruyama; H Yamane; S Tsuchiya; A Ichikawa
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

5.  COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

Authors:  R A Soslow; A J Dannenberg; D Rush; B M Woerner; K N Khan; J Masferrer; A T Koki
Journal:  Cancer       Date:  2000-12-15       Impact factor: 6.860

6.  Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression.

Authors:  Y Higashi; T Kanekura; T Kanzaki
Journal:  Int J Cancer       Date:  2000-06-01       Impact factor: 7.396

Review 7.  Role of the cytoskeletal protein paxillin in oncogenesis.

Authors:  M Sattler; E Pisick; P T Morrison; R Salgia
Journal:  Crit Rev Oncog       Date:  2000

Review 8.  Cyclooxygenase-2 and carcinogenesis.

Authors:  S M Prescott; F A Fitzpatrick
Journal:  Biochim Biophys Acta       Date:  2000-03-27

9.  Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.

Authors:  F A Attiga; P M Fernandez; A T Weeraratna; M J Manyak; S R Patierno
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

Review 10.  Transforming growth factor-beta and breast cancer: Cell cycle arrest by transforming growth factor-beta and its disruption in cancer.

Authors:  J Donovan; J Slingerland
Journal:  Breast Cancer Res       Date:  2000-02-21       Impact factor: 6.466

View more
  7 in total

1.  PGE(2) is a UVR-inducible autocrine factor for human melanocytes that stimulates tyrosinase activation.

Authors:  Renny J Starner; Lindy McClelland; Zalfa Abdel-Malek; Alex Fricke; Glynis Scott
Journal:  Exp Dermatol       Date:  2010-05-25       Impact factor: 3.960

Review 2.  A Review of Prostanoid Receptors: Expression, Characterization, Regulation, and Mechanism of Action.

Authors:  Roger G Biringer
Journal:  J Cell Commun Signal       Date:  2020-09-24       Impact factor: 5.782

3.  Expression of cyclooxygenase 2, microsomal prostaglandin E synthase 1, and EP receptors is increased in rat oesophageal squamous cell dysplasia and Barrett's metaplasia induced by duodenal contents reflux.

Authors:  T J Jang; S K Min; J D Bae; K H Jung; J I Lee; J R Kim; W S Ahn
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

4.  The EP1 subtype of prostaglandin E2 receptor: role in keratinocyte differentiation and expression in non-melanoma skin cancer.

Authors:  R L Konger; S D Billings; N C Prall; T M Katona; S C Dasilva; C R J Kennedy; S Badve; S M Perkins; P T Lacelle
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2009-07-22       Impact factor: 4.006

5.  Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function.

Authors:  Namita Kundu; Xinrong Ma; Dawn Holt; Olga Goloubeva; Suzanne Ostrand-Rosenberg; Amy M Fulton
Journal:  Breast Cancer Res Treat       Date:  2008-09-16       Impact factor: 4.872

Review 6.  The role of the EP receptors for prostaglandin E2 in skin and skin cancer.

Authors:  J E Rundhaug; M S Simper; I Surh; S M Fischer
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

7.  Topical application of a platelet activating factor receptor agonist suppresses phorbol ester-induced acute and chronic inflammation and has cancer chemopreventive activity in mouse skin.

Authors:  Ravi P Sahu; Samin Rezania; Jesus A Ocana; Sonia C DaSilva-Arnold; Joshua R Bradish; Justin D Richey; Simon J Warren; Badri Rashid; Jeffrey B Travers; Raymond L Konger
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.